Johnson & Johnson 3Q Revenues: $15.9 billion (+3%) 3Q Earnings: $3.3 billion (+30%) YTD Revenues: $48.6 billion (+8%) YTD Earnings: $10.2 billion (+25%) Comments: Worldwide Pharmaceutical sales were flat at $6.1 billion in the quarter, with an operational decline of 2.5% and a positive impact from currency of 2.7%. Domestic sales were down 6%, while international sales increased 10% (3% from operations and 7% from currency). Velcade, Remicade, Topamax and Risperdal Consta per...